PMID- 16468954
OWN - NLM
STAT- MEDLINE
DCOM- 20060606
LR  - 20230124
IS  - 1600-6135 (Print)
IS  - 1600-6135 (Linking)
VI  - 6
IP  - 3
DP  - 2006 Mar
TI  - Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates 
      and outcomes in highly HLA-sensitized patients.
PG  - 459-66
AB  - Intravenous immunoglobulin (IVIG) products are derived from pooled human plasma 
      and have been used for the treatment of primary immunodeficiency disorders for 
      more than 24 years. Shortly after their introduction, IVIG products were also 
      found to be effective in the treatment of autoimmune and inflammatory disorders. 
      Over the past 2 decades, the list of diseases where IVIG has a demonstrable 
      beneficial effect has grown rapidly. These include Kawasaki disease, 
      Guillain-Barre syndrome, myasthenia gravis, dermatomyositis and demyelinating 
      polyneuropathy. Recently, we have described a beneficial effect on the reduction 
      of anti-HLA antibodies with subsequent improvement in transplantation of highly 
      HLA-sensitized patients as well as a potent anti-inflammatory effect that is 
      beneficial in the treatment of antibody-mediated rejection (AMR). These 
      advancements have enabled transplantation of patients previously considered 
      untransplantable. These studies and relevant mechanism(s) of action will be 
      discussed here.
FAU - Jordan, S C
AU  - Jordan SC
AD  - Comprehensive Transplant Center, Cedars-Sinai Medical Center, UCLA School of 
      Medicine, University of California-Los Angeles, Los Angeles, CA, USA. 
      sjordan@cshs.org
FAU - Vo, A A
AU  - Vo AA
FAU - Peng, A
AU  - Peng A
FAU - Toyoda, M
AU  - Toyoda M
FAU - Tyan, D
AU  - Tyan D
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Transplant
JT  - American journal of transplantation : official journal of the American Society of 
      Transplantation and the American Society of Transplant Surgeons
JID - 100968638
RN  - 0 (HLA Antigens)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (gamma-Globulins)
SB  - IM
CIN - Am J Transplant. 2006 Jun;6(6):1497. PMID: 16686780
MH  - Graft Rejection/*drug therapy/immunology
MH  - Graft Survival/*drug effects
MH  - HLA Antigens/*immunology
MH  - Humans
MH  - Immunoglobulins, Intravenous/*administration & dosage/therapeutic use
MH  - *Kidney Transplantation
MH  - Treatment Outcome
MH  - gamma-Globulins/*administration & dosage/therapeutic use
RF  - 35
EDAT- 2006/02/14 09:00
MHDA- 2006/06/07 09:00
CRDT- 2006/02/14 09:00
PHST- 2006/02/14 09:00 [pubmed]
PHST- 2006/06/07 09:00 [medline]
PHST- 2006/02/14 09:00 [entrez]
AID - S1600-6135(22)02606-5 [pii]
AID - 10.1111/j.1600-6143.2005.01214.x [doi]
PST - ppublish
SO  - Am J Transplant. 2006 Mar;6(3):459-66. doi: 10.1111/j.1600-6143.2005.01214.x.